News

We’ll keep you up to date! On top of current topics, you will also find out more about our past “highlights”.

ARTCLINE appoints Dirk Hessel as Managing Director and Prepares the Market Entry for Innovative Septic Shock Treatment

23rd September 2024

ARTCLINE successfully completes capital increases of EUR 4.4 million

25th March 2024

First Patients enrolled in EU randomized Trial of ARTCLINEs Immune-cell Therapy System for treatment of septic shock

8th August 2022

ARTCLINE receives 4 million euros and starts clinical trial with novel immune cell therapy for septic shock patients

15th June 2022

Journal “TRANSFUSION” publishes article on new cell therapy method of ARTCLINE

15th January 2022

The Federal Ministry for Economic Affairs and Energy promotes ARTCLINE’s extracorporeal immune cell therapy

5th December 2020

ARTCLINE successfully completed a capital increase of EUR 4 million

9th March 2020

USPTO grants to ARTCLINE the US patent for a “METHOD FOR PRODUCING A LEUKOCYTE PREPARATION”

13th August 2019

ARTCLINE receives innovation grant from the BMBF for its extracorporeal immune cell therapy

12th December 2018

European patent granted to ARTCLINE for a “LEUKOCYTE PREPARATION” and the respective production method

6th December 2017

Publication of results from Part II of the current “EISS-1” study

28th June 2016

ARTCLINE is certified according to ISO 13485

26th August 2013

Project “Bioactive Cell Filters” – ARTCLINE publishes final report

11th November 2011

Innovation forum “Bioactive Cell Filters” and ARTCLINE present a new therapy option for treating sepsis

15th March 2011

ARTCLINE published promising results of the “EISS-1” clinical study

3rd March 2011

If you have general or news-related questions or comments: info@artcline.de